This randomized , double blind , double-dummy , 4-period crossover trial compared single doses of corifollitropin alfa 150 g ( therapeutic dose ) , corifollitropin alfa 240 g ( supratherapeutic dose ) , and moxifloxacin 400 mg ( positive control ) with placebo .